State Street Corp Buys 41,421 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

State Street Corp lifted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 2.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,130,279 shares of the medical research company's stock after purchasing an additional 41,421 shares during the quarter. State Street Corp owned about 4.17% of Charles River Laboratories International worth $419,601,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CRL. Tortoise Investment Management LLC boosted its holdings in shares of Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company's stock valued at $27,000 after buying an additional 57 shares in the last quarter. Wolff Wiese Magana LLC purchased a new stake in Charles River Laboratories International in the third quarter worth about $32,000. Assetmark Inc. increased its stake in shares of Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock valued at $37,000 after purchasing an additional 173 shares in the last quarter. Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of Charles River Laboratories International by 219.3% during the second quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company's stock valued at $58,000 after purchasing an additional 193 shares during the last quarter. Finally, Covestor Ltd boosted its position in shares of Charles River Laboratories International by 40.9% in the 3rd quarter. Covestor Ltd now owns 327 shares of the medical research company's stock worth $65,000 after purchasing an additional 95 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on CRL. Robert W. Baird lowered their price objective on Charles River Laboratories International from $191.00 to $190.00 and set a "neutral" rating for the company in a research note on Friday, September 20th. StockNews.com lowered shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Thursday, November 7th. Evercore ISI upped their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an "in-line" rating in a research note on Thursday, November 7th. CLSA lowered shares of Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price objective for the company. in a report on Monday, November 18th. Finally, Bank of America downgraded Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their target price for the company from $250.00 to $215.00 in a research note on Wednesday, October 2nd. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat, Charles River Laboratories International currently has a consensus rating of "Hold" and an average target price of $214.38.

Charles River Laboratories International Stock Performance

CRL stock traded down $4.70 during midday trading on Tuesday, reaching $197.05. 415,330 shares of the company's stock traded hands, compared to its average volume of 618,153. The stock's 50-day moving average is $194.19 and its 200 day moving average is $203.56. The stock has a market cap of $10.08 billion, a P/E ratio of 25.25, a PEG ratio of 4.95 and a beta of 1.38. Charles River Laboratories International, Inc. has a 52-week low of $176.48 and a 52-week high of $275.00. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping analysts' consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $975.99 million. During the same period last year, the firm earned $2.72 EPS. Charles River Laboratories International's revenue for the quarter was down 1.6% compared to the same quarter last year. As a group, analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).